June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Anti-VEGF induced nephropathy following intravitreal administration: a potential toxicity.
Author Affiliations & Notes
  • Deepak Mangla
    Department of Ophthalmology, Northwestern University, Chicago, Illinois, United States
  • Manjot Gill
    Department of Ophthalmology, Northwestern University, Chicago, Illinois, United States
  • Susan E Quaggin
    Northwestern Department of Medicine, Feinberg Cardiovascular Institute, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Deepak Mangla, None; Manjot Gill, None; Susan Quaggin, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 202. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Deepak Mangla, Manjot Gill, Susan E Quaggin; Anti-VEGF induced nephropathy following intravitreal administration: a potential toxicity.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):202.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Anti-VEGF induced kidney injury has rarely been described in the ophthalmology literature. Consideration of this potential toxicity will become increasingly important as the use and indications of anti-VEGF treatment are broadened.

Methods : This is a case report and review of the literature. We present a patient with neovascular AMD receiving anti-VEGF injections who developed declining renal function. We reviewed both the opthalmology literature and nephrology literature for renal injury secondary to alterations in systemic VEGF levels.

Results : After extensive work-up to exclude other etiologies for renal failure including renal biopsy, injections were halted temporarily per the nephrology service. A renal biopsy showed chronic tubule-interstitial disease.

Conclusions : The nephrology team believed the renal injury to be secondary to ocular anti-VEGF injections. Studies have shown that serum VEGF levels are depressed following intraocular anti-VEGF injection, however the extent is dictated by each drug’s pharmacokinetics. Ophthalmologists should be aware of this entity as patients may require pretreatment counseling particularly for those with pre-existing renal disease. Close monitoring of the patient may be required in order to assess renal function before and after the intravitreal administration of anti-VEGF.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×